Joon Young Choi1, Hyoung Kyu Yoon2, Jae Ha Lee3, Kwang Ha Yoo4, Bo Yeon Kim5, Hye Won Bae5, Young Kyoon Kim1, Chin Kook Rhee1. 1. Division of Pulmonary, Allergy and Critical Care Medicine, Department of Internal Medicine, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, South Korea. 2. Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, Yeouido St Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, South Korea. 3. Division of Pulmonology, Department of Internal Medicine, Inje University College of Medicine, Haeundae Paik Hospital, Busan, South Korea. 4. Division of Pulmonary, Allergy and Critical Care Medicine, Department of Internal Medicine, Konkuk University School of Medicine, Seoul, South Korea. 5. Health Insurance Review & Assessment Service, Wonju, South Korea.
Abstract
BACKGROUND: Previous studies have found that the prescription rates of inhaled corticosteroid (ICS) were considerably low although it is recommended as the optimal asthma treatment. The aim of this study was to analyze the current status of ICS prescription for asthma patients in the South Korea. METHODS: We evaluated quality assessment data based on nationwide Health Insurance Review and Service (HIRA) database from July 2013 to June 2014. ICS prescription rates in asthma patients were analyzed by types and specialty of medical institutions. Also, we graded medical institutions by their ICS prescription rate. In addition, ICS prescription rates were calculated by patient gender, age, and insurance type. RESULTS: This study included 831,613 patients and 16,804 institutions in the analysis. The overall mean ICS prescription rate was 22.58%. Tertiary hospitals had the highest mean prescription rate (84.16%) whereas primary healthcare clinics had the lowest (20.71%). By specialty, internal medicine physicians prescribed ICS more frequently compared to other specialists. Of all, 47.17% of medical institutions prescribed ICS to <10% of asthma patients, while less than 6% of institutions prescribed ICS to >80% of asthma patients. Also, we found that female and patients with age >90 or <20 years exhibited lower ICS prescription rate. CONCLUSIONS: The ICS prescription rate was found to be inadequate, given the importance of ICS as an asthma treatment. The prescription rates were especially low in primary healthcare clinics, and by specialists in fields other than internal medicine.
BACKGROUND: Previous studies have found that the prescription rates of inhaled corticosteroid (ICS) were considerably low although it is recommended as the optimal asthma treatment. The aim of this study was to analyze the current status of ICS prescription for asthma patients in the South Korea. METHODS: We evaluated quality assessment data based on nationwide Health Insurance Review and Service (HIRA) database from July 2013 to June 2014. ICS prescription rates in asthma patients were analyzed by types and specialty of medical institutions. Also, we graded medical institutions by their ICS prescription rate. In addition, ICS prescription rates were calculated by patient gender, age, and insurance type. RESULTS: This study included 831,613 patients and 16,804 institutions in the analysis. The overall mean ICS prescription rate was 22.58%. Tertiary hospitals had the highest mean prescription rate (84.16%) whereas primary healthcare clinics had the lowest (20.71%). By specialty, internal medicine physicians prescribed ICS more frequently compared to other specialists. Of all, 47.17% of medical institutions prescribed ICS to <10% of asthma patients, while less than 6% of institutions prescribed ICS to >80% of asthma patients. Also, we found that female and patients with age >90 or <20 years exhibited lower ICS prescription rate. CONCLUSIONS: The ICS prescription rate was found to be inadequate, given the importance of ICS as an asthma treatment. The prescription rates were especially low in primary healthcare clinics, and by specialists in fields other than internal medicine.
Entities:
Keywords:
Health Insurance Review and Service (HIRA); Inhaled corticosteroid (ICS); Korea; asthma; nationwide-population-based
Authors: Chin Kook Rhee; Hyoung Kyu Yoon; Kwang Ha Yoo; Young Sam Kim; Sei Won Lee; Yong Bum Park; Jin Hwa Lee; Yuri Kim; Kyungjoo Kim; Jinhee Kim; Yeon Mok Oh; Sang Do Lee Journal: COPD Date: 2013-10-10 Impact factor: 2.409
Authors: Christopher K W Lai; Teresita S De Guia; You-Young Kim; Sow-Hsong Kuo; Amartya Mukhopadhyay; Joan B Soriano; Pham Long Trung; Nan Shan Zhong; Norzila Zainudin; B M Z Zainudin Journal: J Allergy Clin Immunol Date: 2003-02 Impact factor: 10.793
Authors: Helen K Reddel; Lutz Beckert; Angela Moran; Tristram Ingham; Rosario D Ampon; Matthew J Peters; Susan M Sawyer Journal: Respirology Date: 2017-08-09 Impact factor: 6.424
Authors: Robert S Zeiger; James W Baker; Michael S Kaplan; David S Pearlman; Michael Schatz; Steven Bird; Carolyn Hustad; Jonathan Edelman Journal: Respir Med Date: 2004-09 Impact factor: 3.415